Pulmatrix, Inc.
PULM Healthcare Biotechnology
Pulmatrix, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7.8 million, up 6.96% from fiscal 2023. In the quarter to June 2026, revenue fell 99.9%, EPS grew 31.0% and free cash flow grew 41.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow PULM
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Gross Profit |
— | — | — | — |
+8 more quarters Free account |
R&D Expenses |
0.00 | 0.00 | 0.00 | 0.01 | |
SG&A Expenses |
1.04 | 1.29 | 0.91 | 0.86 | |
Operating Income |
(1.05) | (1.29) | (0.91) | (0.87) | |
Non-operating Income/Expense |
0.01 | 0.12 | (0.02) | (0.01) | |
| (1.04) | (1.17) | (0.93) | (0.88) | ||
Income after Tax |
(1.04) | (1.17) | (0.93) | (0.88) | |
Dividends (Preferred) |
0.02 | — | — | — | |
Net Income Common |
(1.05) | (1.17) | (0.93) | (0.88) | |
EPS (Basic) |
(0.29) | (0.32) | (0.25) | (0.24) | |
EPS (Diluted) |
(0.29) | (0.32) | (0.25) | (0.24) | |
Shares (Basic, Weighted) |
3.65 | 3.65 | 3.65 | 3.65 | |
Shares (Diluted, Weighted) |
3.65 | 3.65 | 3.65 | 3.65 | |
EBIT Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBT margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBITDA |
(1.05) | (1.29) | (0.91) | (0.87) | |
EBIT |
(1.05) | (1.29) | (0.91) | (0.87) | |
Income from Continuous Operations |
(1.04) | (1.17) | (0.93) | (0.88) | |
Consolidated Net Income/Loss |
(1.04) | (1.17) | (0.93) | (0.88) | |
EPS (Basic, from Continuous Ops) |
(0.28) | (0.32) | (0.25) | (0.24) | |
EPS (Diluted, from Cont. Ops) |
(0.28) | (0.32) | (0.25) | (0.24) | |
EPS (Basic, Consolidated) |
(0.28) | (0.32) | (0.25) | (0.24) | |
EPS (Diluted, Consolidated) |
(0.28) | (0.32) | (0.25) | (0.24) | |
Shares (Diluted, Average) |
3.65 | 3.65 | 3.65 | 3.65 | |
EBITDA Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating Cash Flow Margin |
0.00% | 0.00% | 0.00% | 0.00% |